# Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo

Study · id `cardio:ct-nct05949008` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05949008](<https://clinicaltrials.gov/study/NCT05949008>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05949008

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 150 participants.

## Technical summary

Registry record NCT05949008. Randomized; double masking; primary purpose prevention. Start 2023-11-22 (actual); primary completion 2027-10-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT05949008, source copy `cardio:ctgov-nct05949008-2026-06-08`, retrieved 2026-10-26)
- Started: 2023-11-22 (actual) (ClinicalTrials.gov record NCT05949008, source copy `cardio:ctgov-nct05949008-2026-06-08`, retrieved 2026-10-26)
- Primary completion: 2027-10-30 (anticipated) (ClinicalTrials.gov record NCT05949008, source copy `cardio:ctgov-nct05949008-2026-06-08`, retrieved 2026-10-26)
- Completion: 2028-07-30 (anticipated) (ClinicalTrials.gov record NCT05949008, source copy `cardio:ctgov-nct05949008-2026-06-08`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05949008, source copy `cardio:ctgov-nct05949008-2026-06-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05949008-2026-06-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo
- Condition: NIDDM
- Condition: Obesity
- Intervention (Drug): Metformin Extended Release (ER) Oral Tablet
- Intervention (Drug): Placebo
- Lead sponsor: University of California, Los Angeles
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: University of California, Los Angeles (`cardio:org-university-of-california-los-angeles`)

## Provenance

Content hash: cebf4fc568000026d247241f912aa643f8e2823c1a8fb67a730924faf8d3eeb0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
